Presentation, ACC (American College of Cardiology) 2013 by M. Natsuaki M.D.
The 3-year clinical results of NOBORI 2 study show consistently low occurrence of clinical events throughout the trial.
February 23, 2013
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial has been published
The Lancet, Volume 381, Issue 9867, Pages 651 - 660
October 23, 2012
Three-year clinical outcomes from the first randomized study of DES with biodegradable polymer in Japanese population showed sustained, high efficacy Nobori®
Presented at TCT 2012 by Dr. T. Kimura.
May 17, 2012
The three-year data from the large NOBORI 2 Study presented during EuroPCR 2012 confirmed the excellent and sustained performance of the Nobori® Drug Eluting Stent in the longer term
May 16, 2011
One-year results of COMPARE II trial have demonstrated the equivalent safety and efficacy of Nobori® to Xience/Promus
Pieter Smits presented the data for the primary endpoint during the late breaking trial sessions at EuroPCR 2012.All news
Site map |
Legal and Privacy Information
© Terumo Europe N.V. | Webdesign: Mediaction